HUMANIGEN, INC.

Patent Applications and Registrations

Patent applications and USPTO patent grants for HUMANIGEN, INC..The latest application filed is for "materials and methods for treating cancer".

Company Profile

16.9.32

HUMANIGEN, INC. - Burlingame CA
HUMANIGEN, INC - Burlingame CA US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Trademarks

Patent Activity

Patent	Date
Materials And Methods For Treating Cancer App 20220040229 - DURRANT; Cameron ; et al.	2022-02-10
Methods Of Treating Immunotherapy-related Toxicity Using A Gm-csf Antagonist App 20220025034 - DURRANT; Cameron ; et al.	2022-01-27
Methods Of Treating Immunotherapy-related Toxicity Using A Gm-csf Antagonist App 20210322547 - Durrant; Cameron ; et al.	2021-10-21
Methods For Treating Coronavirus Infection And Resulting Inflammation-induced Lung Injury App 20210309733 - DURRANT; Cameron ; et al.	2021-10-07
Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist Grant 11,130,805 - Durrant , et al. September 28, 2	2021-09-28
Methods Of Treating Immunotherapy-related Toxicity Using A Gm-csf Antagonist App 20210290677 - DURRANT; Cameron ; et al.	2021-09-23
Materials And Methods For Treating Cancer App 20210284714 - DURRANT; Cameron ; et al.	2021-09-16
Methods Of Treating Immunotherapy-related Toxicity Using A Gm-csf Antagonist App 20210269518 - DURRANT; Cameron ; et al.	2021-09-02
Epha3 Directed Car-t Cells For Treatment Of Tumors App 20210246215 - DURRANT; Cameron ; et al.	2021-08-12
Methods Of Treating Immunotherapy-related Toxicity Using A Gm-csf Antagonist App 20210230262 - DURRANT; Cameron ; et al.	2021-07-29
Methods Of Treating Immunotherapy-related Toxicity Using A Gm-csf Antagonist App 20210130488 - DURRANT; Cameron ; et al.	2021-05-06
Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab Grant 10,927,168 - Durrant , et al. February 23, 2	2021-02-23
Immunoglobulin variable region cassette exchange Grant 10,919,983 - Bebbington , et al. February 16, 2	2021-02-16
Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity Grant 10,899,831 - Durrant , et al. January 26, 2	2021-01-26
Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist Grant 10,870,703 - Durrant , et al. December 22, 2	2020-12-22
Methods Of Treating Immunotherapy-related Toxicity Using A Gm-csf Antagonist App 20200354443 - DURRANT; Cameron ; et al.	2020-11-12
Methods Of Treating Immunotherapy-related Toxicity Using A Gm-csf Antagonist App 20190338023 - DURRANT; Cameron ; et al.	2019-11-07
Methods Of Treating Immunotherapy-related Toxicity Using A Gm-csf Antagonist App 20190322735 - Durrant; Cameron ; et al.	2019-10-24
Methods Of Treating Immunotherapy-related Toxicity Using A Gm-csf Antagonist App 20190284271 - DURRANT; Cameron ; et al.	2019-09-19
Epha3 Antibodies For The Treatment Of Pulmonary Fibrosis App 20190270821 - YARRANTON; Geoffrey T	2019-09-05
Methods Of Treating Immunotherapy-related Toxicity Using A Gm-csf Antagonist App 20190194343 - DURRANT; Cameron ; et al.	2019-06-27

Company Registrations

SEC

0001293310

HUMANIGEN, INC of DELAWARE

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.